To Compare The Clinical Efficacy And Safety Of Rituximab Combined With Fludarabine,Cyclophosphamide(FCR) And Cyclophosphamide Combined With Doxorubicin,Vincristine And Prednisone Acetate Chemotherapy(CHOP) In The Treatment Of Chronic Lymphocytic Leukemia

Objective:To compare the clinical efficacy and safety of rituximab combined with fludarabine,cyclophosphamide(FCR)and cyclophosphamide combined with doxorubicin,vincristine and prednisone acetate regimen(CHOP)in the treatment of chronic lymphocytic leukemia,and to provide a reference of treatment options for the clinical treatment of chronic lymphocytic leukemia.Methods:A total of 40 patients with chronic lymphocytic leukemia were selected from the Department of Hematology of the People's Hospital of Huaibei City from March 2010 to March 2014.All patients were divided into Observation Group and Control Group by the random number table,and there were 20 cases in each group.The patients in Control Group received CHOP chemotherapy regimen.The patients in Observation Group received regimen.Treatment for 28 days was as a course of treatment for All patients in two groups,and the treatment duration was 4 treatment courses.The shortterm clinical efficacy(Clinical Remission Rate)in two groups was compared.White blood cell count and absolute number of lymphocytes in the peripheral blood was measured before and after treatment in both groups.Minimal Residual Disease(MRD)were observed after treatment in both groups.At the same time,the duration of symptoms and signs such as fever,fatigue,pain,bloating and edema was recorded,and adverse drug reactions were also recorded during treatment.Results:(1)There was no significant difference in age,sex,Binet clinical stage,ZAP70 expression and abnormal chromosome karyotype abnormality in two groups(P> 0.05).(2)After treatment,there were 11 cases of CR in observation group,7 cases of PR in total,90.00% of RR,8 cases of CR in control group,6 cases of PR and 70.0% of RR.The remission rate of observation group was higher than that of control group There is an increasing trend,but the difference is not statistically significant(P> 0.05).(3)White blood cell count and the absolute number of lymphocytes in the peripheral blood after treatment in two group were significantly decreased after treatment with statistically significant difference(P <0.05).White blood cell count and the absolute number of lymphocytes in the peripheral blood after treatment in Observation Group were significantly decreased compared with those in Control Group after treatment with statistically significant difference(P <0.05)(4)The positive rate of MRD in Observation Group had the increasing trend compared that in Control Group with no significant difference statistically(P >0.05).(5)The duration of symptoms and signs such as fever,fatigue,pain,bloating and edema in Observation Group were significantly shorter than those in the control group(P <0.05).(6)The incidence of liver and kidney dysfunction and the total incidence of adverse drug reactions were significantly lower in Observation Group than those in Control Group(P <0.05).The incidence of mucosal inflammation,gastrointestinal reaction,granulocyte deficiency and the thrombocytopenia had the increasing trend compared that in Control Group with no signifiant difference statistically(P >0.05).Conclusion:Treatment of rituximab combined with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia has certain advantage than the treatment of cyclophosphamide combined with doxorubicin,vincristine and prednisone acetate regimen(CHOP)regarding the clinical efficacy and safety.But this results need to be further confirmed by a large sample of clinical study.